Search results
Zealand Pharma says drug shows improvement in fatty liver disease patients
Reuters via AOL· 4 days agoThe company said the data from the trial in patients with metabolic dysfunction-associated steatohepatitis (MASH) was unintentionally and temporarily leaked ahead of its scheduled ...
Madrigal, 89bio Tumble After Lilly's Weight-Loss Drug Tackles MASH
Investor's Business Daily· 5 days agosteatohepatitis, or MASH, could eventually help Eli Lilly to rival Madrigal Pharmaceuticals....
Viking Therapeutics Stock Crumbles Despite Potential 'Best-In-Class' Liver Disease Drug
Investor's Business Daily· 6 days agoViking Therapeutics stock crumbled Tuesday despite seemingly positive test results for a drug that...
DEADLINE REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Akero...
Morningstar· 5 days agoFaruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Akero Therapeutics, Inc. (“Akero” or the “Company”) (NASDAQ: AKRO) and reminds investors ...
SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against Akero...
Morningstar· 5 days agoPomerantz LLP announces that a class action lawsuit has been filed against Akero Therapeutics, Inc. (“Akero” or the “Company”) (NASDAQ: AKRO). Such investors are advised to contact Danielle ...
Eli Lilly details NASH effects of weight loss drug (NYSE:LLY)
Seeking Alpha· 5 days agoEli Lilly (LLY) posts detailed mid-stage results highlighting the benefits of its weight loss drug...
Lilly's tirzepatide was superior to placebo for MASH resolution, and more than half of patients...
StreetInsider· 1 day agoThe efficacy estimandi showed 51.8%, 62.8% and 73.3% of participants taking 5 mg, 10 mg and 15 mg, respectively, achieved an absence of MASH with no worsening of fibrosis on liver histology ...
Viking's MASH drug scored where Madrigal's didn't, but shares fall on lack of direction
FierceBiotech· 6 days agoViking had already reported that the trial met its primary endpoint, with patients experiencing...
89bio (NASDAQ:ETNB) Shares Gap Down to $8.30
ETF DAILY NEWS· 4 days ago89bio, Inc. (NASDAQ:ETNB – Get Free Report)’s share price gapped down prior to trading on Wednesday . The stock had previously closed at $8.30, but opened at $7.70. 89bio shares last traded ...
Stock Market Revs To Highs On Nvidia, CrowdStrike, Yields: Weekly Review
Investor's Business Daily· 3 days agoThe Nasdaq and S&P 500 hit record highs, thanks to lower Treasury yields and positive news from...